Archive for March 27th, 2012

NOVAVAX Launches Phase II Clinical Trial of Seasonal Influenza Vaccine

27 March, 2012

Via Scoop.itVirology News

ROCKVILLE, Md. — Novavax, Inc. today announced that it has begun enrollment in a Phase II clinical trial of its quadrivalent seasonal influenza virus-like particle (VLP) vaccine candidate. This randomized, …

Via finance.yahoo.com

Salk announces polio vaccine — History.com This Day in History — 3/26/1953

27 March, 2012

Via Scoop.itVirology News

On March 26, 1953, American medical researcher Dr. Jonas Salk announces on a national radio show that he has successfully tested a vaccine against poliomyelitis, the virus that causes the crippling disease of polio.

Via www.history.com

The Wrong Policy Prescription for Pakistan’s Vaccine Program

27 March, 2012

Via Scoop.itVirology News

Just because legislating immunization coverage works in the United States doesn’t mean it will work in Pakistan. The main reason is that the drivers of under-vaccination in Pakistan and the United States are fundamentally different.

Via www.huffingtonpost.com

CIDRAP >> Fouchier anticipates resuming H5N1 studies soon

27 March, 2012

Via Scoop.itVirology News

“Fouchier told the audience that virulence is a tough issue to describe and needs to be clearly defined. He said the virus was virulent in ferrets that were inoculated deep within their lungs, and it was virulent in those who were sickened via the aerosol route, though they didn’t die.

“There’s a lot of quotes in the press that are simply wrong,” he said, adding that the definition of virulence touches on other factors such as dose, immune status of the host, and previous exposure to other types of flu. Fouchier said full publication of both studies would help clarify questions scientists and observers have about virulence of the lab-modified viruses.

During today’s webcast, Racaniello asked for more details about the study, but Fouchier said the NSABB asked him not to disclose details about the methods or mutations.

However, he said his group found a number of mutations in common when they sequenced the viruses that had made the jump to airborne spread. “Most of those were pretty interesting,” he said, adding that some of the mutations are the same ones Kawaoka’s group found, though that group took a different approach to the study. “That was a shock to me and to Yoshi,” he said.”

 

Meaning that we should be out there LOOKing for them…thanks, Vincent!

Image courtesy Russell Kightley Media

Via www.cidrap.umn.edu

MedImmune receives FDA approval for FluMist Quadrivalent vaccine

27 March, 2012

Via Scoop.itVirology News

FluMist Quadrivalent, a vaccine to prevent seasonal influenza in people ages 2 years through 49 years, has been approved today by the U.S. Food and Drug Administration.

Via www.news-medical.net

Antiviral Research – A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease

27 March, 2012

Via Scoop.itVirology News

We thus demonstrate for the first time that cattle can be clinically protected against FMDV challenge following a DNA prime-protein boost strategy, and particularly when DNA vaccine is combined with GM-CSF and delivered by electroporation.

 

Thanks MicrobeTweets!

Via www.sciencedirect.com